Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 408

Sort by

Sort Order Select

Journal Articles

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE

Blood (2024) 144 (26): 2706–2717.

https://doi.org/10.1182/blood.2024024667

Published: 2024

Includes: Supplemental data

Journal Articles

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV , ZAP-70, and MRD

Ekaterina Kim, Shih-Shih Chen, Mariela Sivina, Hyunsoo Hwang, Xuelin Huang, Alessandra Ferrajoli, Nitin Jain, William G. Wierda, Dominik Wodarz, Nicholas Chiorazzi, Jan A. Burger

Blood (2024) 144 (25): 2678–2681.

https://doi.org/10.1182/blood.2024025683

Published: 2024

Includes: Supplemental data

Journal Articles

Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1

Blood (2024) 144 (Supplement 1): 883.

https://doi.org/10.1182/blood-2024-199708

Published: 2024

Journal Articles

A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Jan A. Burger, Ekaterina Kim, Gitanjali Jayachandran, Wanda Lopez, Ghayas C. Issa, Musa Yilmaz, Mahesh Swaminathan, Jo Ishizawa, Alexandre Bazinet, Yesid Alvarado Valero, Nitin Jain, William G. Wierda, Alessandra Ferrajoli

Blood (2024) 144 (Supplement 1): 1868.

https://doi.org/10.1182/blood-2024-200331

Published: 2024

Journal Articles

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2024-211454

Published: 2024

Journal Articles

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood (2024) 144 (Supplement 1): 1855.

https://doi.org/10.1182/blood-2024-211110

Published: 2024

Journal Articles

Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia

Daniel Nguyen, Hagop Kantarjian, Nicholas J. Short, Nitin Jain, Fadi G. Haddad, Musa Yilmaz, Alessandra Ferrajoli, Tapan M. Kadia, Yesid Alvarado Valero, Abhishek Maiti, Marianne Zoghbi, Jayastu Senapati, Rebecca Garris, Min Zhao, Marina Konopleva, Farhad Ravandi, Elias Jabbour

Blood (2024) 144 (Supplement 1): 1439.

https://doi.org/10.1182/blood-2024-208854

Published: 2024

Journal Articles

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial

Jan A. Burger, Ekaterina Kim, Gitanjali Jayachandran, Thomas Mathew, Koji Sasaki, Yesid Alvarado Valero, Danielle Hammond, Fadi G. Haddad, William G. Wierda, Alessandra Ferrajoli

Blood (2024) 144 (Supplement 1): 4631.

https://doi.org/10.1182/blood-2024-198701

Published: 2024

Journal Articles

Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update

Blood (2024) 144 (Supplement 1): 4194.

https://doi.org/10.1182/blood-2024-210642

Published: 2024

Journal Articles

First-Line Treatment Choice and Risk of Other Malignancies in US Veterans Diagnosed with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Helen Ma, Sameer A. Parikh, Roberta Santos Azevedo, Susan M. O'Brien, Pankaj Gupta, Alessandra Ferrajoli

Blood (2024) 144 (Supplement 1): 5038.

https://doi.org/10.1182/blood-2024-207780

Published: 2024

Journal Articles

Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53 -Mutated Chronic Lymphocytic Leukemia

Anjali Lankford, Mahesh Swaminathan, Amrit S. Gonugunta, Himachandana Atluri, Hannah Goulart, Koji Sasaki, Guilin Tang, Rashmi Kanagal-Shamanna, Jan A. Burger, Alessandra Ferrajoli, Hagop Kantarjian, William G. Wierda, Nitin Jain

Blood (2024) 144 (Supplement 1): 3246.

https://doi.org/10.1182/blood-2024-208974

Published: 2024

Journal Articles

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2024-206801

Published: 2024

Journal Articles

Atezolizumab Combined with Venetoclax and Obinutuzumab for Frontline CLL

Patrick K. Reville, Sogand Sajedi, Alessandra Ferrajoli, Jan A. Burger, Michael J. Keating, Naveen Garg, Qing Deng, Michael R. Green, Hussein A. Abbas, William G. Wierda, Nitin Jain

Blood (2024) 144 (Supplement 1): 1014.

https://doi.org/10.1182/blood-2024-206306

Published: 2024

Journal Articles

Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2024) 144 (Supplement 1): 2903.

https://doi.org/10.1182/blood-2024-207962

Published: 2024

Journal Articles

Impact of High-Risk Cytogenetics (HR-CTG) on the Outcome of Newly Diagnosed Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Frontline Blinatumomab (Blina) and/or Inotuzumab Ozogamicin (Ino) Containing Hypercvad (HCVAD) Therapy

Jayastu Senapati, Elias Jabbour, Nicholas J. Short, Guilin Tang, Fadi G. Haddad, Nitin Jain, Ghayas C. Issa, Tapan M. Kadia, Naval Daver, Alessandra Ferrajoli, Monica Kwari, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Patrice Eric Nasnas, Naveen Pemmaraju, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian

Blood (2023) 142 (Supplement 1): 1500.

https://doi.org/10.1182/blood-2023-181379

Published: 2023

Journal Articles

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update

Blood (2023) 142 (Supplement 1): 968.

https://doi.org/10.1182/blood-2023-182944

Published: 2023

Journal Articles

Nelarabine (NEL), Pegylated Asparginase (PEG) and Venetoclax (VEN) Incorporated to HCVAD Chemotherapy in the Frontline Treatment of Adult Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL)

Blood (2023) 142 (Supplement 1): 963.

https://doi.org/10.1182/blood-2023-179562

Published: 2023

Journal Articles

NK Cell Dysfunction in CLL Is Mediated through SHP-1 Signaling and Is Associated with Poor Prognosis

Blood (2023) 142 (Supplement 1): 1895.

https://doi.org/10.1182/blood-2023-189671

Published: 2023

Journal Articles

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Blood (2023) 142 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2023-190712

Published: 2023

Journal Articles

Updated Results from a Phase II Study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia

Daniel Nguyen, Hagop M. Kantarjian, Nicholas J. Short, Nitin Jain, Fadi G. Haddad, Musa Yilmaz, Alessandra Ferrajoli, Tapan M. Kadia, Yesid Alvarado Valero, Abhishek Maiti, Cedric Nasnas, Lewis Nasr, Rebecca Garris, Marina Y. Konopleva, Farhad Ravandi, Elias Jabbour

Blood (2023) 142 (Supplement 1): 4245.

https://doi.org/10.1182/blood-2023-190902

Published: 2023

NARROW

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV , ZAP-70, and MRD

Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1

A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial

Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update

First-Line Treatment Choice and Risk of Other Malignancies in US Veterans Diagnosed with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53 -Mutated Chronic Lymphocytic Leukemia

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Atezolizumab Combined with Venetoclax and Obinutuzumab for Frontline CLL

Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Impact of High-Risk Cytogenetics (HR-CTG) on the Outcome of Newly Diagnosed Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Frontline Blinatumomab (Blina) and/or Inotuzumab Ozogamicin (Ino) Containing Hypercvad (HCVAD) Therapy

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update

Nelarabine (NEL), Pegylated Asparginase (PEG) and Venetoclax (VEN) Incorporated to HCVAD Chemotherapy in the Frontline Treatment of Adult Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL)

NK Cell Dysfunction in CLL Is Mediated through SHP-1 Signaling and Is Associated with Poor Prognosis

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Updated Results from a Phase II Study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only